Matthias Zaiß

686 total citations
25 papers, 201 citations indexed

About

Matthias Zaiß is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Matthias Zaiß has authored 25 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Hematology. Recurrent topics in Matthias Zaiß's work include Advanced Breast Cancer Therapies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Matthias Zaiß is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Matthias Zaiß collaborates with scholars based in Germany, Austria and Switzerland. Matthias Zaiß's co-authors include Goran Matic, Gerd Schmitz, Emma Chapman, G. Rothe, Reinhard Andreesen, B. Hennemann, Leoni A. Kunz‐Schughart, Michael Rehli, Jochen Grassinger and Annegret Rehm and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Matthias Zaiß

21 papers receiving 197 citations

Peers

Countries citing papers authored by Matthias Zaiß

Since Specialization

Citations

This map shows the geographic impact of Matthias Zaiß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Zaiß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Zaiß more than expected).

Fields of papers citing papers by Matthias Zaiß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Zaiß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Zaiß. The network helps show where Matthias Zaiß may publish in the future.

Co-authorship network of co-authors of Matthias Zaiß

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Zaiß. A scholar is included among the top collaborators of Matthias Zaiß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Zaiß. Matthias Zaiß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM) 2025 ·Leukemia ·Florian H. Heidel, Valerio De Stefano, Matthias Zaiß, Jens Kisro, Eva Gückel, (unknown), Mike W. Zuurman, Kirsi Manz, Kenneth Bryan, (unknown), Martin Grießhammer, Jean‐Jacques Kiladjian	0
2	Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV. 2024 ·Journal of Clinical Oncology ·Nadia Harbeck, Michael Braun, Oleg Gluz, Peter Schmid, Monika Graeser, Andreas D. Hartkopf, Oliver Hoffmann, (unknown), Silke Polata, (unknown), Raquel von Schumann, (unknown), (unknown), Matthias Zaiß, (unknown), Iris Scheffen, Matthias Christgen, Hans Kreipe, Ulrike Nitz, Sherko Küemmel	2
3	Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry 2024 ·International Journal of Cancer ·Marc Thill, (unknown), Anja Welt, Arnd Nusch, Matthias Zaiß, (unknown), (unknown), Kai G. Ringwald, (unknown), (unknown), (unknown), Martina Jänicke, H. Schulz, Volker Hagen, (unknown), Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Thomas Decker	5
4	Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study 2024 ·Annals of Hematology ·Ingo Schwaner, Thomas Kühn, Christoph Losem, Thomas Wolff, Burkhard Otremba, Matthias Zaiß, (unknown), (unknown), Thomas Nösslinger, Davide Rossi	1
5	Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial 2024 ·Oncology Research and Treatment ·Manfred Welslau, Karin Potthoff, Matthias Zaiß, Lothar Müller, Cosima Brucker, Christoph Salat, (unknown), Jens Meiler, Diana Lüftner, Anja Welt, Steffen Dörfel, Volker Hagen, Alexander Stein, Rüdiger Liersch, (unknown), (unknown), (unknown), Corinne Vannier, Norbert Marschner, (unknown)	0
6	Abstract PO1-04-12: Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer – real world outcome data from the German registry platform OPAL 2024 ·Cancer Research ·Marc Thill, (unknown), Anja Welt, Arnd Nusch, Matthias Zaiß, (unknown), (unknown), Kai G. Ringwald, (unknown), (unknown), Martina Jänicke, H. Schulz, Christoph Losem, Volker Hagen, (unknown), Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Thomas Decker	3
7	Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine 2023 ·Cancer Research ·Rupert Bartsch, Nadia Harbeck, (unknown), Matthias Zaiß, Jürgen Terhaag, (unknown), (unknown), Rachel Wuerstlein, (unknown), Diana Lüftner, (unknown), Marija Balić, Christian Jackisch, Volkmar Müller, Gabriel Rinnerthaler, Marcus Schmidt, Khalil Zaman, Timo Schinköthe, (unknown), (unknown)	1
8	Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting 2023 ·Breast Care ·Thomas Decker, Matthias Zaiß, (unknown), Antje Hahn, Volker Hagen, Paul La Rosée, Rüdiger Liersch, Thomas Wolff, (unknown), (unknown), (unknown), Marco Chiabudini, Fee Bengsch, (unknown), Norbert Marschner	2
9	The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice 2023 ·BMC Cancer ·Uwe M. Martens, (unknown), Fee Bengsch, Ludger Sellmann, (unknown), (unknown), Matthias Zaiß, Thomas Decker, Andreas Schneeweiß, Martin Schüler, (unknown), Stefan Zacharias, Norbert Marschner, Benjamin Kasenda, Karin Potthoff, Corinne Vannier	0
10	Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958) 2022 ·Breast Cancer Research and Treatment ·Marc Thill, Pauline Wimberger, Andrea Gräfe, Peter Klare, Kerstin Lüedtke-Heckenkamp, Dietmar Reichert, Matthias Zaiß, (unknown), (unknown), Andreas Schneeweiß	2
11	Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle. 2022 ·Journal of Clinical Oncology ·Nadia Harbeck, Oleg Gluz, Matthias Christgen, Michael Braun, Marc Thill, Pauline Wimberger, Kerstin Lüedtke-Heckenkamp, Monika Graeser, Felix Hilpert, Vesna Bjelic‐Radisic, Katja Krauss, Mathias Warm, Matthias Zaiß, Andreas D. Hartkopf, Marianne Just, Hans Kreipe, Ulrike Nitz, Christine zu Eulenburg, Rachel Wuerstlein, Sherko Küemmel, (unknown)	3
12	Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO 2021 ·Oncology Research and Treatment ·Matthias Zaiß, Jens Uhlig, (unknown), Thomas Decker, Helmar C. Lehmann, (unknown), (unknown), Corinne Vannier, Norbert Marschner	6
13	Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR 2018 ·Current Medical Research and Opinion ·Thomas Fietz, (unknown), H. Schulz, (unknown), Christoph Losem, (unknown), Thomas Wolff, Karin Potthoff, Udo Müller, Matthias Zaiß, Christian M. Kurbacher	9
14	Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study 2014 ·Oncology Research and Treatment ·Volkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, Christian Lerchenmüller, (unknown), Ursula Vehling‐Kaiser, (unknown), (unknown), (unknown), (unknown), Matthias Zaiß	9
15	Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib 2012 ·Onkologie ·Norbert Marschner, Matthias Zaiß	4
16	Differentiation of hematopoietic progenitor cells towards the myeloid and B‐lymphoid lineage by hepatocyte growth factor (HGF) and thrombopoietin (TPO) together with early acting cytokines 2006 ·European Journal Of Haematology ·Jochen Grassinger, (unknown), Matthias Zaiß, Leoni A. Kunz‐Schughart, Reinhard Andreesen, B. Hennemann	9
17	Expression and Function of Homing‐Essential Molecules and Enhanced In Vivo Homing Ability of Human Peripheral Blood‐Derived Hematopoietic Progenitor Cells after Stimulation with Stem Cell Factor 2004 ·Stem Cells ·Christina Hart, (unknown), (unknown), Jochen Grassinger, Matthias Zaiß, Leoni A. Kunz‐Schughart, Reinhard Andreesen, Albrecht Reichle, Ernst Holler, B. Hennemann	24
18	CD84 expression on human hematopoietic progenitor cells 2003 ·Experimental Hematology ·Matthias Zaiß, (unknown), Michael Rehli, Annegret Rehm, Leoni A. Kunz‐Schughart, Reinhard Andreesen, B. Hennemann	29
19	Activation of Lymphocytes Inhibits Human Monocyte to Macrophage Differentiation 2001 ·Immunobiology ·Stefan W. Krause, Matthias Zaiß, Marina Kreutz, Reinhard Andreesen	6
20	Whole blood analysis of reticulated platelets: Improvements of detection and assay stability 1998 ·Cytometry ·Goran Matic, Emma Chapman, Matthias Zaiß, G. Rothe, Gerd Schmitz	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact